| Project Number | pCODR 10186 |
|---|---|
| Brand Name | Cabometyx |
| Generic Name | Cabozantinib |
| Strength | 20 mg, 40 mg & 60 mg |
| Tumour Type | Gastrointestinal |
| Indication | Hepatocellular Carcinoma |
| Funding Request | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Review Status | Under Review |
| Pre Noc Submission | Yes |
| NOC Date | November 8, 2019 |
| Manufacturer | Ipsen Biopharmaceuticals Canada Inc. |
| Sponsor | Ipsen Biopharmaceuticals Canada Inc. |
| Submission Date | October 16, 2019 |
| Submission Deemed Complete | October 30, 2019 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 30, 2019 |
| Check-point meeting (target date) | January 8, 2020 |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
